InsidersTradesSigma
Total declarations
Company
▲ Purchases (22 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
22
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
+7.9%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Schuetz Thomas J., Chairman & CEO. Officer active across 1 company, notably Compass Therapeutics, Inc.. Cumulatively, 33 disclosures have been published. Breakdown: 22 buys · 0 sell. Total volume traded: €1.1m. Activity tracked since 16 November 2021. The latest transaction was disclosed on 8 February 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Schuetz Thomas J.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations33 total
36,687 shares@ US$6.524.7% of flowCommon StockSEC:0001171843-26-000722:0
46,777 shares@ US$5.355.0% of flowCommon StockSEC:0001171843-26-000205:0
250,000 shares@ US$5.1725.7% of flowCommon StockSEC:0001171843-26-000060:0
44,025 shares@ US$4.836.6% of flowCommon StockSEC:0001171843-25-007400:0
10,000 shares@ US$2.110.4% of flowCommon StockSEC:0001171843-25-003462:0
Canonical exit: 25 Aug 2025 (T+90)
41,687 shares@ US$3.505.4% of flowCommon StockSEC:0001171843-25-000735:0
58,054 shares@ US$1.864.0% of flowCommon StockSEC:0001171843-25-000195:0
44,782 shares@ US$1.452.3% of flowCommon StockSEC:0001171843-24-000714:0
637,500 shares@ US$1.9343.4% of flowCommon StockSEC:0001171843-24-000178:0
44,025 shares@ US$1.502.4% of flowCommon StockSEC:0001171843-23-007222:0
10,000 shares@ US$3.371.2% of flowCommon StockSEC:0001171843-23-001588:0
Canonical exit: 8 Jun 2023 (T+90)
20,000 shares@ US$3.982.9% of flowCommon StockSEC:0001171843-23-001175:0
Canonical exit: 28 May 2023 (T+90)
20,000 shares@ US$3.862.8% of flowCommon StockSEC:0001171843-23-000974:0
Canonical exit: 16 May 2023 (T+90)
500,000 shares0Common StockSEC:0001171843-23-000851:0
20,000 shares@ US$4.052.9% of flowCommon StockSEC:0001171843-23-000557:0
Canonical exit: 1 May 2023 (T+90)
20,000 shares@ US$4.193.0% of flowCommon StockSEC:0001171843-23-000419:0
Canonical exit: 24 Apr 2023 (T+90)
10,000 shares@ US$2.320.9% of flowCommon StockSEC:0001171843-22-006282:0
Canonical exit: 27 Dec 2022 (T+90)
15,000 shares@ US$2.271.4% of flowCommon StockSEC:0001171843-22-006243:0
Canonical exit: 25 Dec 2022 (T+90)
15,000 shares@ US$3.031.8% of flowCommon StockSEC:0001171843-22-006005:0
Canonical exit: 6 Dec 2022 (T+90)
15,000 shares@ US$2.831.6% of flowCommon StockSEC:0001171843-22-005905:0
Canonical exit: 30 Nov 2022 (T+90)
15,000 shares@ US$3.051.7% of flowCommon StockSEC:0001171843-22-005700:0
Canonical exit: 15 Nov 2022 (T+90)
15,000 shares@ US$2.641.5% of flowCommon StockSEC:0001171843-22-005567:0
Canonical exit: 8 Nov 2022 (T+90)
15,000 shares@ US$2.581.5% of flowCommon StockSEC:0001171843-22-005231:0
Canonical exit: 30 Oct 2022 (T+90)
20,000 shares@ US$2.800.016% mcap10.7% of flowCommon StockSEC:0001171843-22-004440:0
Canonical exit: 19 Sept 2022 (T+90)
20,000 shares@ US$2.341.0% of flowCommon StockSEC:0001171843-22-004408:0
Canonical exit: 14 Sept 2022 (T+90)
25 of 33 declarations
About Schuetz Thomas J.
Schuetz Thomas J. is President and Chief Executive Officer of Compass Therapeutics, Inc. (XNAS). He has 33 filings in total, and across the 33 sampled filings, the transactions recorded are acquisitions, with EUR 1116072 of buys and EUR 0 of sells, over the period from 2021-11-18 to 2026-02-10.
